Vertex appoints Michel Lagarde to board as tenth director

VERTEX PHARMACEUTICALS INC / MA

Michel Lagarde appointed to Vertex board effective Oct 5, 2023; board expands to 10.
Lagarde is EVP and COO of Thermo Fisher Scientific; background in pharma services and private equity.
Received $400,000 RSU award vesting in October 2024; standard non-employee director compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michel Lagarde

Director

VRTX · VERTEX PHARMACEUTICALS INC / MA

Effective: 2023-10-05
Filed: October 5, 2023, 7:59 PM ET

On October 3, 2023, Michel Lagarde was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”), effective on October 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michel Lagarde was appointed as Director at VERTEX PHARMACEUTICALS INC / MA.

Action: appointed
Role: Director

Exact text from the filing

On October 3, 2023, Michel Lagarde was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”), effective on October 5, 2023.

View on SEC.gov

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.